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Abstract: SOST encodes the sclerostin protein, which acts as a key extracellular inhibitor of the
canonical Wnt pathway in bone, playing a crucial role in skeletal development and bone homeostasis.
The objective of this work was to assess the functionality of two variants previously identified
(the rare variant rs570754792 and the missense variant p.Val10Ile) and to investigate the physical
interactors of the SOST proximal promoter region in bone cells. Through a promoter luciferase
reporter assay we show that the minor allele of rs570754792, a variant located in the extended TATA
box motif, displays a significant decrease in promoter activity. Likewise, through western blot studies
of extracellular and intracellular sclerostin, we observe a reduced expression of the p.Val10Ile mutant
protein. Finally, using a circular chromosome conformation capture assay (4C-seq) in 3 bone cell
types (MSC, hFOB, Saos-2), we have detected physical interactions between the SOST proximal
promoter and the ECR5 enhancer, several additional enhancers located between EVT4 and MEOX1
and a distant region containing exon 18 of DHX8. In conclusion, SOST presents functional regulatory
and missense variants that affect its expression and displays physical contacts with far reaching
genomic sequences, which may play a role in its regulation within bone cells.
Keywords: sclerostin; bone; 4C-seq; luciferase reporter assay; HBM
1. Introduction
Sclerostin (encoded by the SOST gene) is a potent antagonist of the canonical Wnt path-
way and of bone formation, exerting its function by blocking LRP5/6 co-receptors [1,2]. To
perform this function, sclerostin binds to LRP4, which enhances its suppressive effect [3–5].
Sclerostin is a monomeric protein with a NxI motif and an eight-membered cysteine knot
motif, all of them implicated in LRP5/6 binding [6–8].
In humans, SOST mutations are associated with inherited high bone mass conditions
characterized by excessive bone formation, with a sclerosis phenotype particularly promi-
nent in the skull, jaw and long bones. The clinical spectrum of these conditions ranges from
severe craniodiaphyseal dysplasia to non-pathological high bone mass, with the severity
of the condition being inversely proportional to sclerostin abundance. Craniodiaphyseal
dysplasia (CDD, MIM 122860) is the most severe sclerostin bone dysplasia, characterized by
an absence of extracellular sclerostin and a dominant negative effect. It is an extremely rare
autosomal dominant condition, with less than 20 cases reported [9,10]. Sclerosteosis (MIM
269500) is another severe sclerostin disease with autosomal recessive inheritance [11,12].
Nine loss-of-function mutations (either truncating or missense) have been described in
SOST [12–19]. Additionally, three loss-of-function mutations in LRP4, have been described
in sclerosteosis-2 [4,20]. Van Buchem’s disease (MIM 239100), a third sclerostin clinical
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entity, is caused by a 52-kb deletion of a regulatory region located 32 kb downstream of
SOST and necessary for the correct expression of the gene [21,22]. The difference in severity
lies in that in patients with Van Buchem, wild-type sclerostin is low, whereas in patients
with sclerosteosis it is absent [23,24]. In line with these findings, a heterozygous truncating
mutation in SOST has been associated with the non-pathological High Bone Mass (HBM)
phenotype, which is characterized by unusually dense bones and a very strong skeleton
practically eliminating fracture occurrence [25–28]. Furthermore, it was described that
mutations in LRP5 causing the HBM phenotype showed a loss of affinity of LRP5 for
sclerostin [29,30].
Sclerostin is mainly expressed in mature osteocytes, although relatively high levels of
mRNA have been found in different tissues [31]. In addition, SOST/sclerostin expression
is altered in certain pathogenic conditions, including postmenopausal osteoporosis, os-
teoarthritis and rheumatic joint disease [32]. Genetically modified mice add another line of
evidence to the role of SOST in bone mineral density (BMD) determination: Sost-knock-out
(KO) mice show high BMD and bone strength, with a high number of osteoblasts and
increased bone formation that reproduce the phenotype observed in patients with scleros-
teosis or Van Buchem’s disease [33,34]. In contrast, mice that overexpress this gene present
with low bone mass, lower bone resistance, low number of osteoblasts and reduced bone
formation [35–38].
The transcription of SOST is finely regulated by a large number of signals. SOST
expression is controlled by the proximal promoter region (~1.4 kb upstream of SOST) and
by a 225-bp bone-specific distal enhancer called ECR5 (Evolutionary conserved region
5), located 32 kb downstream of the gene [31,39]. ECR5 is deleted in patients with Van
Buchem’s disease, and its deletion in mice causes a drastic decrease in sclerostin levels in
osteocytes [39]. ECR5 stimulates the expression of SOST, in part through the binding of the
transcription factor Myocyte-enhancer factor 2c (Mef2c) [35,39].
Humanized monoclonal antibodies against sclerostin have been developed for the
treatment of different bone disorders such as osteoporosis or osteogenesis imperfecta,
and they have been approved in Japan, US, EU and Canada [40–44]. Antibody treatment
against sclerostin stimulates bone formation, decreases bone resorption and, thus, increases
bone mass and strength, and decreases the risk of fragility fracture in both animals and
humans [40–42,44–46].
Taking into account the crucial role of SOST in bone growth, we hypothesized that
partial loss-of-function mutations in its gene might be associated with variations in BMD
in the general population. In this line, we previously identified 2 variants in SOST that
captured our interest. First, the rare variant rs570754792 located in the extended TATA box,
which was only present in 3 women with low bone mass; and second, the low-frequency
variant rs17882143 (p.Val10Ile), which modified the signal peptide of sclerostin, and whose
minor allele was associated with high BMD [47].
Our objective in this work was to assess the functionality of these variants and to
detect the main physical interactors of the SOST proximal promoter. We verified the loss of
function of rs570754792 and rs17882143, which produced a decrease in gene expression and
protein abundance, respectively. In addition, we were able to detect physical interactions
of the SOST proximal promoter with several enhancers in the region, including the ECR5
distal enhancer.
2. Results
2.1. The Minor Allele of a Variant in the Extended TATA Box of SOST Displays Lower
Transcriptional Capacity
The rare variant rs570754792 (MAF = 0.004464, gnomAD v2.1.1) lies in the SOST
proximal promoter, specifically in the extended TATA box. To test its effect, we performed
a luciferase reporter assay in Saos-2 cells, testing a 520-bp fragment, which contains either
of the variant alleles. Our results show that this region harbors promoter activity (20-fold
increased transcription vs. empty vector, for the wild-type allele; Figure 1) and show
significant differences between the two alleles tested, where the minor allele displays
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lower transcription capacity (about 25% less than the major allele; Figure 1). The COL1A1
promoter (SP construct in [48]), used as positive control, showed 31.6-fold increased
promoter activity compared to the empty vector (Figure 1).
Figure 1. Functional testing of a rare variant in the extended TATA box of SOST. rs570754792 (g.41836179 G > A in
GRCh37.p13) belongs to the extended TATA box of SOST, which is encoded in the negative strand of chromosome 17,
thereby generating a C > T substitution. In black, a scheme of the location of the variant (asterisk) in the SOST upstream
region and in green the constructs tested. We used the luciferase gene without promoter as a negative control and the
COL1A1 promoter as a positive control. Relative luciferase units (RLU; see material & methods) are normalized to the
negative control. The experiment was performed four times in triplicate. **** indicates p < 0.0001.
2.2. Lower Protein Abundance for the Minor Allele of rs17882143, Both in the Intracelullar and
Extracellular Spaces
The rs17882143 SNP is a missense change (p.Val10Ile; MAF = 0.0109 gnomAD v.2.1.1)
within the signal peptide of the sclerostin protein. To assess whether the change might affect
the subcellular localization of the mutated protein or its abundance, we performed western
blot studies with extracellular and intracellular protein extracts (Figure 2). In addition
to this mutation, we tested 5 of the most frequent sclerostin mutations in the general
population according to gnomAD (p.Arg19His, p.Gly150Arg, p.Asn53del, p.Ala28Val,
p.Pro111Gln; Figure 2A), as well as two positive controls (p.Val21Leu and p.Cys167Arg;
Figure 2A) whose absence in the extracellular space had been previously described [10,17].
All these changes are depicted along the sclerostin protein domains in Figure 2A. We
verified that the positive control proteins SOST-p.Val21Leu and SOST-p.Cys167Arg showed
a dramatic decrease in the extracellular space. However, while the SOST-p.Cys167Arg
showed an increase in the amount of intracellular protein, the SOST-p.Val21Leu showed a
decrease in intracellular levels (Figure 2B,C). Similarly to the results of these two positive
control proteins (p.Val21Leu and p.Cys167Arg), we observed a lower abundance of SOST-
p.Val10Ile and SOST-p.Gly150Arg proteins in the extracellular space and, for the SOST-
p.Val10Ile, SOST-p.Val21Ile, SOST-p.Ala28Val, SOST-p.Asn53del and SOST-p.Pro111Gln, a
lower abundance in the intracellular compartment. The other mutant proteins behaved
similarly to the WT protein (Figure 2B,C).
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Figure 2. Western blot of variant sclerostin proteins transfected into Saos-2 cells. Variants were generated by in vitro
mutagenesis into a SOST expression vector and subsequently transfected and heterologously expressed in Saos-2 cells.
(A) Tested amino acid variants, displayed along a scheme of the sclerostin, with indication of specific domains (SP: signal
peptide; CTCK: C-terminal cystine-knot; NXI:NXI(R/K) sequence motif; asterisks denote the glycosylation N-linked
(GlcNAc) asparagine). In red, the mutation present in a patient with sclerosteosis [17]; in purple, the mutation found in
a patient with CDD [10] and in pale pink, the mutation associated with high BMD [47] (B) Detection of sclerostin in the
extracellular media. Above, image of the first biological replicate; below, quantification of the sclerostin bands from images
of 6 equivalent blots, normalizing to the extracellular levels of WT sclerostin. (C) Detection of intracellular sclerostin. Above,
image of the first biological replica of sclerostin and their corresponding tubulin; below, the quantification of the ratios of
sclerostin/tubulin protein from images of 3 equivalent blots, normalizing to the ratio of WT sclerostin/tubulin.
2.3. Physical Interaction between the SOST Proximal Promoter and Several Distal Regulatory
Elements in Bone Cells
To identify important regulators of SOST expression presence in three bone-related
cells (mesenchymal stem cells—MSC-; human fetal osteoblasts—hFOB- and an osteosar-
coma cell line—Saos-2-), we performed a 4C-seq assay using the SOST proximal promoter
(chr17:41838135-41838123, GRCh37/hg19) as a viewpoint (Figure 3). Using an algorithm
to discern the significant contacts, we only observed interactions of this viewpoint with
sequences included in a genomic region spanning 288 kb centromeric to the viewpoint.
Within this region, we confirmed the strong physical interaction between the proximal
promoter and the ECR5 distal enhancer in the 3 cell types. Moreover, we found interactions
in the three cell types between the viewpoint and several genomic regions located between
MEOX1 and ETV4, described as enhancers according to GeneHancer [49] and displaying
strong H3K4me1, H3K4me2, H3K4me3, H3K27ac and H2AFz histone marks in osteoblasts
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(ENCODE; Supplementary Figure S1). In addition, we observed an interaction with a
region containing exon 18 of the DHX8 gene that displays strong H3K4me1 and H3K27Ac
histone marks in osteoblasts (ENCODE), suggesting a potential regulatory role for this
region, too. Finally, we saw a significant interaction with the DHX8 promoter in hFOB and
Saos-2 cells, which displays H3K4me2, H3K4me3, H3K27ac, H3K79m3 and H2AFz histone
marks in osteoblasts (ENCODE; Figure 3 and Supplementary Figure S1).
Figure 3. Chromatin interactions of the SOST proximal promoter region as detected by 4C-
seq in human fetal osteoblasts (hFOB), mesenchymal stem cells (MSC) and the Saos-2 cell
line. Panel (A): Graphical representation of a 350-kb Chr.17 region containing SOST and
all the genomic elements found to interact with it displaying both the read depths (Interac-
tion strength) and their corresponding significance (arched lines). The dashed vertical line
marks the SOST promoter, used as the viewpoint. Color scale corresponds to the strength
of the significant interactions. Panel (B): Genes in this region: DHX8_1 (ENST00000262415.3),
DHX8_2 (ENST00000540306.1), ETV4_1 (ENST00000319349.5), ETV4_2 (ENST00000545954.1),
ETV4_3 (ENST00000591713.1), ETV4_4 (ENST00000545089.1), MEOX1_1 (ENST00000520305.1),
MEOX1_3 (ENST00000393661.2), SOST (ENST00000301691.2), DUSP3 (ENST00000226004.3), MPP3
(ENST00000398389.4) from GRCh37/hg19. In purple the ECR5 position [35]. Panel (C): Representa-
tion of the GeneHancer (GH) track (enhancers -grey- and promoters -red-).
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2.4. The rs17882143 (p.Val10Ile) Variant Present in One HBM Woman
To further explore the putative genetic association of SOST with bone density phe-
notypes, we resequenced the SOST gene and the ECR5 enhancer, in 11 HBM women
(described in [50]. We identified eight variants in SOST and one variant in ECR5, all of
them previously described (Table 1). Interestingly, we found the variant p.Val10Ile in
heterozygosity in one HBM woman (HBM13) with a high sum Z-score (lumbar spine +
femoral neck BMD Z-score = 5.2). In addition, we found the ECR5 variant rs552004150 in
heterozygosity in another HBM woman (HBM16) with a Sum Z-score = 5.3. However, it
did not co-segregate with the phenotype in the HBM16 family (Supplementary Figure S2a).
This variant lies approximately 50 bp from the MEF2C binding site and does not modify
the binding of any known transcription factor according to TRANSFAC (Supplemen-
tary Figure S2b). Variants rs1237278, rs851058, rs10534024, rs17882143, rs17886183 and
rs17881550, found in our HBM cohort, are listed as eQTLs for different genes and tissues in
the GTEx database (Supplementary Table S1). In addition, variants rs1237278, rs851058 and
rs17885799 are described as affecting the binding site of various transcription factors, and
the rare variant rs17885799 may generate a new exonic splicing enhancer (ESE) according
to SNP function prediction (Supplementary Table S2). Furthermore, SNPs rs17883310 and
rs17886183 show allele-specific differences in miRNA binding predictions (Supplementary
Table S2).
Table 1. Variants in SOST and ECR5 found in women with an HBM phenotype.
Position rs Number Type MAF (EUR) MAF (HBM Cohort) Predicted Functionality
SOST
g.41838229C > T rs1237278 5′ UP 0.355 (C) 0.45 (C) eQTL; TFBS
g.41837719G > A rs851058 5′ UP 0.402 (A) 0.35 (A) eQTL; TFBS
g.41837510_41837512del rs10534024 5′ UP 0.352 (TCCTCCT) 0.45 (TCCTCCT) eQTL
p.Val10Ile rs17882143 M 0.018 (T) 0.05 (T) eQTL T; B; LB
c.-22G > A rs17885799 5′ UTR - 0.05 (A) TFBS, ESE
c.*320C > T rs17883310 3′ UTR 0.013 (T) 0.05 (T) miRNA
c.*1004G > A rs17886183 3′ UTR 0.004 (A) 0.05 (A) eQTL miRNA
c.*1266_*1267insG rs17881550 3′ UTR 0.412 (ins) 0.35 (ins) eQTL
ECR5
g.41774092G > A rs552004150 3′ D 0.003 (A) 0.05 (A)
M: Missense variant; 5′ UP: 5′ Upstream; 5′ UTR: 5′ UTR variant; 3′ UTR: 3′ UTR variant; 3′ D 3′ downstream variant; MAF(EUR) from
1000 genomes. eQTL: described as eQTL in GTEx. TFBS: Transcription factor binding site; ESE: Exon Splicing enhancer; T: Tolerated by
SIFT; B: Benign by Polyphen-2; LB: Likely Benign by CADD; miRNA: allelic differences in the miRNA binding prediction.
3. Discussion
Sclerostin is an important bone protein, strongly associated with different bone scle-
rosing dysplasias. In this work, we undertook a functional study to test two sclerostin
variants (rs570754792 and rs17882143) and to define the physical interactions of the SOST
proximal promoter region. We experimentally demonstrate the partial loss of function of
these two variants that cause a loss of expression (rs570754792) and a reduction of protein
levels (p.Val10Ile). Furthermore, we detect physical interactions of the SOST promoter
with ECR5, with a region containing exon 18 of the DHX8 gene and with several enhancers
between MEOX1 and ETV4, in 3 bone cell types.
Regarding the rare variant rs570754792, it was found in heterozygosity in only
three women of the BARCOS cohort of postmenopausal women of the Barcelona area,
all three with BMD values below the mean (lumbar spine BMD: 0.767, 0.694, 0.822 vs.
0.850 g/cm2) [47]. According to the established inhibitory role of SOST in the canonical
Wnt pathway, we investigated whether SOST was expressed at levels higher than normal
using a luciferase reporter assay. Surprisingly, we observed just the opposite: lower levels
of expression in the presence of the minor allele (T). This result, however, is not totally
unexpected, since the rare variant is part of the extended TATA box, and the major and
minor alleles represent the canonical and non-canonical base at the position -6, respectively.
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At this point it is hard to reconcile the low BMD values observed in the three carriers
and the lower SOST expression levels of the variant. The lack of genomic context of the
luciferase experiments might provide an explanation for these contradictory results. On
the other hand, it may just be that this variant has low penetrance, and in these women
an alternative mechanism is responsible for their phenotype, (i.e., a different mutation
or environmental component with a larger effect, masking that of the mutation in the
extended TATA box of SOST). In fact, it could be a situation similar to that of van Buchem’s
disease, in which two copies of a low expressing allele are needed to show the phenotype.
Using western blot analysis, we studied the expression levels of sclerostin containing
the SNP rs17882143 (SOST-p.Val10Ile). As this variant is located in the signal peptide of the
protein, we expected a lower translocation to the extracellular space. However, we found
lower amounts of it, both in the extracellular and the intracellular compartments, which
seems to indicate a defect in a previous stage to protein translocation and secretion. This
result is supported by an analysis using the SignalIP signal peptide prediction program [51]
that predicts no functional differences in the signal peptide. Our result could be explained
by reduced transcription or translation levels or increased mRNA or protein degradation.
In particular, it has been described that missense mutations can result in an altered sec-
ondary mRNA structure which compromises the accessibility of the protein translational
machinery [52–54]. In our case, this hypothesis is supported by the Mfold web server [55],
which predicts a secondary structure that has a different free energy depending on the
allele of the SOST-p.Val10Ile. The p.Val10Ile mutation is the most frequent SOST missense
variant according to gnomAD (MAF 0.0109). In silico functional predictors scored it as
benign (SIFT; 0.43), tolerated (Polyphen; 0.001) and likely benign (CADD; 0 and REVEL;
0.123). In a previous study of our group [47], this variant showed nominal association with
lumbar spine BMD, where the minor allele (Ile) was protective. Furthermore, we have now
found that a woman with an HBM phenotype (with a sum Z-score of 5.2) is heterozygous
for this variant (Table 1), and it was also detected in 8 additional HBM cases in the work of
Gregson et al. [25]. All things considered, it could be speculated that people carrying this
mutation show high non-pathogenic BMD due to a reduction of sclerostin expression.
The SOST-p.Gln150Arg protein showed a decreased secretion to the extracellular space
compared to the WT. This mutation, which is present in the general population with a
frequency of 0.000333, is the third most frequent missense mutation in SOST and functional
predictors consider it deleterious (SIFT; 0.02), possibly damaging (Polyphen; 0.651) or likely
benign (CADD; 23 and REVEL; 0.295). Similarly to SOST-p.Val10Ile, it could be speculated
that people carrying p.Gln150Arg may present a non-pathogenic HBM due to low levels of
sclerostin in the extracellular space. In the future, BMD analyses of carriers will be helpful
to test this prediction.
Regarding the two mutants previously described that we used as positive controls,
we obtained similar results to those described by Piters et al., for p.Cys167Arg [17], while
we obtained some discrepant results for p.Val21Leu, compared to data from Kim et al. [10].
In particular, we found that intracellular protein abundance of SOST-p.Val21Leu was
approximately 50% of that of WT, while Kim et al. [10] showed values similar to wild-type
sclerostin. Technical differences, including different cell types (HEK293 vs. Saos-2) and
antibodies (anti-myc vs. anti-sclerostin), may explain this discrepancy.
Finally, through 4C-seq we showed for the first time the physical interaction between
ECR5 and SOST in 3 bone-relevant cell lines. Further, we identified the interaction of the
proximal SOST promoter with several putative enhancer elements between MEOX1 and
EVT4, which display regulatory histone marks in osteoblasts (ENCODE). Even though
they appear as non-tissue specific elements according to GeneHancer, in the future it will
be interesting to investigate the role of these enhancers in bone-specific SOST expression.
We also identified a significant interaction between the promoter and a distal regulatory
element overlapping exon 18 of DHX8, a gene encoding a spliceosome component, which
may be unrelated to bone mass. In the overall emerging picture, several long-distance
enhancers may participate in the regulation of SOST in bone cells. Whether they work in
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an additive way or as alternative redundant enhancers is an interesting question for future
research.
Sclerostin is a key component of the canonical Wnt pathway in bone and, as such, it
plays a crucial role in skeletal development and bone homeostasis. A detailed understand-
ing of its developmental and tissue regulation together with the knowledge of the effect of
variation at its locus is key to developing prediction algorithms or therapeutic strategies
based on this gene/protein. Our results add functional evidence for the participation of
the p.Val10Ile variant in non-pathogenic HBM phenotype and also provide regulatory
evidence for certain enhancer elements in the SOST genomic region. In the future, more
experiments are needed to gain a functional understanding of the regulation of sclerostin
expression.
4. Materials and Methods
4.1. Cell Culture
The human osteosarcoma cell line Saos-2 was used for luciferase reporter assays, west-
ern blot experiments and 4C-seq assays. It was obtained from the American Type Culture
Collection (ATCC®, Manassas, VA, USA) and grown in Dulbecco’s Modified Eagle Medium
(DMEM; Sigma-Aldrich, St Louis, MO, USA), supplemented with 10% Fetal Bovine Serum
(FBS; Gibco, Life Technologies, Carlsbad, CA, USA) and 1% penicillin/streptomycin (p/s;
Gibco, Life Technologies, Carlsbad, CA, USA), at 37 ◦C and 5% of CO2. Human fetal os-
teoblast 1.19 (hFOB) cell line and human medulla-derived mesenchymal stem cells (MSCs)
were used for 4C-seq assays. The hFOB 1.19 cell line was obtained from ATCC (ATCC®,
Manassas, VA, USA) and grown in DMEM: F12 (1:1) medium without phenol red (Gibco,
Life Technologies, Carlsbad, CA, USA), supplemented with 10% FBS and 0.3 mg/mL
Geneticin (Gibco, Life Technologies, Carlsbad, CA, USA), at 34 ◦C and 5% of CO2. MSCs
were kindly provided by Dr. José Manuel Quesada Gómez, from Instituto Maimónides de
Investigación Biomédica, Hospital Universitario Reina Sofía, Córdoba, Spain [56]. These
cells were grown in alpha-MEM medium (Gibco, Life Technologies, Carlsbad, CA, USA),
supplemented with 10% FBS, 1% p/s and 1x Glutamax (Gibco, Life Technologies, Carlsbad,
CA, USA), at 37 ◦C and 5% of CO2.
4.2. Luciferase Reporter Constructs, SOST Expression Vectors and Site-Directed Mutagenesis
The 520-bp fragment of the SOST upstream region (chr17:41,836,117-41,836,636,
GRCh37/hg19) was PCR-amplified and cloned into the pGL3 basic Luciferase Re-
porter Vector (Promega, Madison, WI, USA). Constructs harboring the two alleles
of the rare variant rs570754792 were cloned using the KpnI and BglII restriction
sites (Primers used: ATACTAGGTACCGTCAAACAGAAACGCCTT and TATCTTAA-
GATCTCTTCCAGTAGCACAGGC). The SOST/pcDNA3.1+ expression vector was a
gift from Xi He (Addgene plasmid # 10842; http://n2t.net/addgene: 10842; RRID:
Addgene_10842). The missense mutations p.Val10Ile, p.Arg19His, p.Val21Leu (pos-
itive control), p.Ala28Val, p.Asn53del, p.Pro111Gln, p.Gly150Arg and p.Cys167Arg
(positive control) were introduced into the expression vector using the QuickChange
Site-Directed Mutagenesis kit (Agilent, Santa Clara, CA, USA), following the manufac-
turer’s instructions. In all cases, the presence of point mutations and absence of errors
were verified through Sanger sequencing.
4.3. Luciferase Gene Reporter Assay
For the luciferase gene reporter assay, 3 × 105 Saos-2 cells per well were cultured
in 6-well plates, 24 h before the transfection. We transfected the cells with the renilla
luciferase vector (pRL-TK) and either the empty pGL3 basic vector (negative control),
the SOST-upstream region with each of the two alleles, or the basal promoter of COL1A1
(positive control from [48]). The total amount of DNA transfected per well was 2.2 µg.
Fugene HD was used following the manufacturer’s instructions. Forty-eight hours after
transfection, cells were lysed and the luciferase activities of Photinus pyrali and Renilla
Int. J. Mol. Sci. 2021, 22, 489 9 of 14
reniformis were measured using a Glomax Multi+ luminometer (Promega, Madison, WI,
USA), following the instructions of the Dual-luciferase reporter assay system (Promega,
Madison, WI, USA). Each experiment included 3 replicates and was repeated independently
in 4 separate experiments. The ratio of firefly and renilla luciferase measurements was
calculated (relative luciferase units; RLU). All luciferase data were normalized using the
empty vector activity (pGL3-basic).
4.4. Western Blot Assay
For the western blot assay, 3 × 105 Saos-2 cells per well were cultured in 6-well plates,
24 h before transfection. We transfected 2 µg of the SOST expression plasmid (WT or
any of the missense variants: p.Val10Ile, p.Arg19His, p.Val21Leu, p.Ala28Val, p.Asn53del,
p.Pro111Gln, p.Gly150Arg and p.Cys167Arg). For the negative control, we transfected
2 µg of the empty pcDNA3 vector (data not shown). Fugene HD was used following the
manufacturer’s instructions. After 24 h, the medium was changed, reducing from 2 to 1 mL
of DMEM, without FBS or antibiotics. Forty-eight hours after transfection, the supernatant
(conditioned medium) of each condition was collected and the cells were lysed with RIPA
buffer. Proteins in the conditioned medium were concentrated using 10K Amicon Ultra
filters (Merck-Millipore, Burlington, MA, USA). Extracellular proteins (concentrated con-
ditioned medium) and intracellular proteins (RIPA extraction) were quantified using the
PierceTM BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA, USA). Proteins
from concentrated conditioned medium (10 µg/lane) and intracellular proteins (5 µg/lane)
were separated by electrophoresis in an SDS-polyacrylamide gel (SDS-PAGE) and trans-
ferred to a hydrophobic PVDF transfer membrane (Merck-Millipore, Burlington, MA, USA).
We used the ab63097 antibody against sclerostin (Abcam, Cambridge, UK) and antibody
against Tubulin (Abcam, Cambridge, UK) was used as the intracellular loading control. The
images were developed using a peroxidase-conjugated secondary antibody [Anti-Rabbit
IgG (A0545) for sclerostin antibody and Anti-Mouse IgG (A5906) for α-Tubulin antibody
(Sigma-Aldrich, St Louis, MO, USA)]. For the extracellular protein, samples were obtained
from 3 biological replicates that were quantified twice by BCA (ThermoFisher Scientific,
Waltham, MA, USA). Each one of these quantifications was used to perform an SDS-PAGE
experiment, producing a total of 2 experiments for each biological replica. For the intracel-
lular protein, samples were obtained from 3 biological replicates and quantified once by
BCA.
4.5. PCR Amplification and Sequencing
Resequencing of SOST and the SOST enhancer ECR5 was performed in a small cohort
of 11 HBM women described elsewhere [50]. Specifically, we resequenced the complete
coding region, the 5′ and 3′ UTR regions and the intronic flanking regions of SOST, in
addition to 1 Kb of the SOST proximal promoter and the ECR5 enhancer region. PCR-
amplification of each of these fragments was performed using the GoTaq Flexi DNA
polymerase (Promega, Madison, WI, USA). The PCR fragments were analyzed by agarose
gel electrophoresis and purification was done in MultiScreen TM Vacuum Manifold 96-
well plates (Merck Millipore, Burlington, MA, USA). The purified PCR products were
sequenced by the Sanger method in the CCiTUB genomic service (Genómica, Parc Cientific,
Barcelona, Spain), using the BigDye™ Terminator v3.1 Cycle Sequencing Kit. Detection and
electrophoresis were performed on automated capillary sequencer models 3730 Genetic
Analyzer and 3730xl Genetic Analyzer. The sequence of the primers and the conditions
used were previously described [47].
4.6. Bioinformatic Analysis and in Silico Predictions of the Effect of the Variants
To identify and characterize all the variants, we used information from the Ensembl
database GRCh37.p13 (http://www.ensembl.org). Information was sought on the MAF of
each of the variants found in the European population (EUR). We used SIFT (http://sift.bii.a-
star.edu.sg/), PolyPhen (http://genetics.bwh.harvard.edu/pph2/), CADD (https://cadd.gs.
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washington.edu/) and REVEL [57] to test the effect of the missense variants. The SNP Func-
tion Prediction (snpinfo.niehs.nih.gov/snpinfo/snpfunc.html), MirSNP http://bioinfo.bjmu.
edu.cn/mirsnp/), PolymiRTS Database 3.0 (http://compbio.uthsc.edu/miRSNP/search.php)
and MicroSNiPer (http://vm24141.virt.gwdg.de/services/microsniper/) were used to anal-
yse the binding of miRNAs to the variants in the 3′UTR region. Only those results that
coincided with at least two different programs have been considered. The GTEx database
(www.gtexportal.org/home/) was used to identify variants that act as eQTLs. The SNP
Function Prediction (snpinfo.niehs.nih.gov/snpinfo/snpfunc.html) was used to predict tran-
scription factor binding sites (TFBS) and new exonic splicing enhancers (ESE). To characterize
regions that include the variants found, the UCSC Genome Browser GRCh37/hg19 was
enriched with ENCODE data from osteoblasts.
4.7. 4C-Seq
4C-seq was carried out at the Functional Genomics Service of the Centro Andaluz
de Biología del Desarrollo (CABD, Sevilla, Spain). 4C-seq libraries were generated from
Saos-2, hFOB 1.19 and hMSC cell lines as described previously [58,59]. Four-bp cutters were
used as primary (DpnII) and secondary (Csp6I) restriction enzymes. For each cell line, a
total of 1.6 µg of library was PCR amplified (primers used: CCTGCTGTGACATCTTCTGC
and CCATTCAGAGGGGTGTGGATC). Samples were sequenced with Illumina Hi-Seq
technology according to standard protocols at the Genomics Service of the Centro Nacional
de Investigaciones Cardiovasculares (CNIC, Madrid, Spain). 4C-seq data were generated
as described previously [60]. Briefly, raw sequencing data were demultiplexed and mapped
to the corresponding reference genome (GRCh37). Reads located in fragments flanked
by two restriction sites of the same enzyme, in fragments smaller than 40 bp or within a
window of 10 kb around the viewpoint were filtered out. 4C-seq data were normalized by
the total weight of reads within ±2 Mb around the viewpoint.
4C-seq data were analyzed with the AFourC software (Martínez-Gil, N., Herrera, C.,
Gritti, N., Roca-Ayats, N., Ugartondo, N., Garcia-Giralt, N., Ovejero, D., Nogués, X., Garcia-
Fernandez, J., Grinberg, D. & Balcells, S., submitted) following and adapting previously
described pipelines [61,62]. Briefly, we assumed that the 4C signal profile relative to the
viewpoint v with coordinate xv on chromosome N is formed by three independent contri-
butions: a constant background level, a negative exponential representing the monotonic
decay of the 4C signal with the genomic distance from the viewpoint [62] and N gaussians
representing the interaction peaks:








To estimate the genomic distance-dependent monotonic decay, we assumed a symmet-
ric trend around the viewpoint and performed the exponential fit on the left-right averaged
profile. Statistically significant peaks were detected using a p-value of 0.0005. The software
package is publicly available at https://github.com/Nikoula86/AFourC.git.
4.8. Statistical Analyses
In the luciferase assays, the differences between the two alleles were evaluated using
the Welch Two Sample t-test, and the homogeneity of variances was confirmed using
Bartlett test and normality was confirmed using Shapiro test. Statistical significance was
set at p-value < 0.05. The statistical evaluation was carried out with Rstudio Version 3.6.1.
The representations were performed using Graphpad (Graphpad Prism 8, San Diego, CA,
USA).
In the analysis of the western blots, we used the ImageJ 1.52a software to quantify the
intensity of the bands and the GraphPad 8 software for the graphical representation of the
means and standard deviations of each mutant sclerostin.
The specific statistics for the 4C-seq experiments have been detailed in Section 4.7.
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